Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy that uses UCSF technology developed by Dr. Scott Baraban, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet syndrome (DS) has been approved by Health Canada.
